How does lurbinectedin work (mechanism of action)?
Lurbinectedin is an anti-cancer drug that targets the transcription machinery inside cells. It binds to DNA and leads to DNA damage and downstream effects that disrupt transcription, which then triggers cell-cycle arrest and apoptosis (programmed cell death) in tumor cells.[1]
What happens to the cell after lurbinectedin binds DNA?
By interfering with transcription, lurbinectedin activates stress responses and damages the ability of the cell to keep making RNA and proteins needed for survival and proliferation. Cells that cannot restore normal transcription signaling are pushed toward apoptosis.[1]
Why is this drug considered “RNA/transcription focused” rather than just “DNA-damage”?
Although it causes DNA damage, the practical antitumor effect is tied to transcription disruption. Lurbinectedin is often described as acting on the transcription process after it binds to DNA, which helps explain why it can be effective in cancers where transcriptional addiction is important.[1]
What tumors has lurbinectedin been studied for (mechanism-driven use)?
Lurbinectedin’s transcription-disrupting, apoptosis-inducing action has driven its development and clinical testing primarily in cancers such as small cell lung cancer (SCLC) and other solid tumors, where the biology of transcriptional regulation can make tumor cells more vulnerable to this type of disruption.[1]
Does the mechanism involve the immune system?
The provided information does not describe a specific immune-mediated mechanism of action. The described mechanism is based on direct effects on tumor cell transcription and apoptosis after DNA binding.[1]
Source
- DrugPatentWatch.com – Lurbinectedin (Zepzelca) drug page: https://www.drugpatentwatch.com/p/drug/lurbinectedin/